Hepatitis C Virus (HCV)

Infectious Diseases
7
Pipeline Programs
2
Companies
15
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
6
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
4100%
+ 3 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
5 programs
1
4
Glecaprevir/PibrentasvirPhase 3Small Molecule1 trial
Glecaprevir/PibrentasvirPhase 3Small Molecule5 trials
Glecaprevir/PibrentasvirPhase 3Small Molecule1 trial
Glecaprevir/pibrentasvirPhase 3Small Molecule1 trial
Glecaprevir/Pibrentasvir Adult FormulationPhase 2/31 trial
Active Trials
NCT03067129Completed129Est. Sep 2022
NCT03089944Completed343Est. Nov 2019
NCT07040319Not Yet Recruiting30Est. Jul 2027
+6 more trials
Bristol Myers Squibb
2 programs
2
Peginterferon Lambda-1aPhase 31 trial
Pegylated Interferon LambdaPhase 31 trial
Active Trials
NCT01754974Completed40Est. Sep 2014
NCT01447394Withdrawn0Est. Aug 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AbbVieGlecaprevir/Pibrentasvir
AbbVieGlecaprevir/Pibrentasvir
AbbVieGlecaprevir/Pibrentasvir
AbbVieGlecaprevir/Pibrentasvir
AbbVieGlecaprevir/Pibrentasvir
AbbVieGlecaprevir/Pibrentasvir
AbbVieGlecaprevir/Pibrentasvir
AbbVieGlecaprevir/pibrentasvir
AbbVieGlecaprevir/Pibrentasvir
Bristol Myers SquibbPeginterferon Lambda-1a
Bristol Myers SquibbPegylated Interferon Lambda
AbbVieGlecaprevir/Pibrentasvir Adult Formulation
AbbVieGlecaprevir/Pibrentasvir
AbbVieGlecaprevir/Pibrentasvir
AbbVieGlecaprevir/Pibrentasvir

Clinical Trials (15)

Total enrollment: 3,752 patients across 15 trials

NCT03781726AbbVieGlecaprevir/Pibrentasvir

Multi-center Study to Transplant Hepatitis-C Infected Kidneys

Start: Apr 2019Est. completion: Dec 202130 patients
Phase 4Completed
NCT04903626AbbVieGlecaprevir/Pibrentasvir

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Start: Aug 2021Est. completion: Sep 2024286 patients
Phase 3Completed
NCT03219216AbbVieGlecaprevir/Pibrentasvir

A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

Start: Jun 2018Est. completion: Mar 2019100 patients
Phase 3Completed
NCT03235349AbbVieGlecaprevir/Pibrentasvir

Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

Start: Sep 2017Est. completion: Feb 2019160 patients
Phase 3Completed
NCT03212521AbbVieGlecaprevir/Pibrentasvir

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Start: Aug 2017Est. completion: Aug 2018230 patients
Phase 3Completed
NCT03089944AbbVieGlecaprevir/Pibrentasvir

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

Start: Apr 2017Est. completion: Nov 2019343 patients
Phase 3Completed
NCT03092375AbbVieGlecaprevir/Pibrentasvir

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

Start: Apr 2017Est. completion: Feb 2020177 patients
Phase 3Completed
NCT03069365AbbVieGlecaprevir/pibrentasvir

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

Start: Mar 2017Est. completion: Jun 2018101 patients
Phase 3Completed
NCT02966795AbbVieGlecaprevir/Pibrentasvir

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

Start: Jan 2017Est. completion: Aug 201884 patients
Phase 3Completed
NCT01754974Bristol Myers SquibbPeginterferon Lambda-1a

Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C

Start: Mar 2013Est. completion: Sep 201440 patients
Phase 3Completed
NCT01447394Bristol Myers SquibbPegylated Interferon Lambda

Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

Start: Mar 2012Est. completion: Aug 20140
Phase 3Withdrawn
NCT03067129AbbVieGlecaprevir/Pibrentasvir Adult Formulation

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

Start: Mar 2017Est. completion: Sep 2022129 patients
Phase 2/3Completed
NCT07040319AbbVieGlecaprevir/Pibrentasvir

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

Start: Feb 2026Est. completion: Jul 202730 patients
Phase 1/2Not Yet Recruiting
NCT07419347AbbVieGlecaprevir/Pibrentasvir

Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data

Start: Feb 2026Est. completion: May 20262,000 patients
N/ANot Yet Recruiting
NCT04577482AbbVieGlecaprevir/Pibrentasvir

Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response

Start: Oct 2020Est. completion: Sep 202242 patients
N/ACompleted

Related Jobs in Infectious Diseases

Senior Recruiter

Invivyd
New Haven, CT (Northeast preferred)
7h ago
$120K - $160K/yr

Senior Associate Scientist (contract), Upstream Polysaccharide Process Development

VaxCyte
San Carlos, California, United States
9h ago
$56/hr

Senior Associate Scientist (contract), Polysaccharide Analytical Development

VaxCyte
San Carlos, California, United States
9h ago
$56/hr

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
13h ago
$179K - $237K/yr

Technician, Operations, DSP/ Technicien(ne) des opérations, DSP

Verona Pharma
CAN - Prince Edward Island - Charlottetown
Yesterday
$47K - $79K/yr

HVAC Maintenance Technician

Verona Pharma
USA - Delaware - Millsboro (Intervet)
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)